

editorials

PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations

T. Helleday 755

Reporting incidental germline variants in the context of day-to-day somatic genomic profiling

G. Mak, M. Moschetta & H.-T. Arkenau 758

special article

Statistical controversies in clinical research: statistical significance—too much of a good thing ...

M. Buyse, S. A. Hurvitz, F. Andre, Z. Jiang, H. A. Burris, M. Toi, W. Eiermann, M.-A. Lindsay & D. Slamon 760

reviews

Molecular classification of gastric cancer

N.-Y. Chia & P. Tan 763

New drugs in acute myeloid leukemia

T. M. Kadia, F. Ravandi, J. Cortes & H. Kantarjian 770

Breakthrough therapies in B-cell non-Hodgkin lymphoma

C. Y. Cheah, N. H. Fowler & M. L. Wang 778

Phosphoproteomics in translational research: a sarcoma perspective

J. Noujaim, L. S. Payne, I. Judson, R. L. Jones & P. H. Huang 787

original articles

precision medicine

Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol

F. Meric-Bernstam, L. Brusco, M. Daniels, C. Wathoo, A. M. Bailey, L. Strong, K. Shaw, K. Lu, Y. Qi, H. Zhao, H. Lara-Guerra, J. Litton, B. Arun, A. K. Eterovic, U. Aytac, M. Routbort, V. Subbiah, F. Janku, M. A. Davies, S. Kopetz, J. Mendelsohn, G. B. Mills & K. Chen 795

Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer

M. R. Jones, K. A. Schrader, Y. Shen, E. Pleasance, C. Ch'ng, N. Dar, S. Yip, D. J. Renouf, J. E. Schein, A. J. Mungall, Y. Zhao, R. Moore, Y. Ma, B. S. Sheffield, T. Ng, S. J. M. Jones, M. A. Marra, J. Laskin & H. J. Lim 801

breast tumors

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial

N. Zdenkowski, J. F. Forbes, F. M. Boyle, G. Kannourakis, P. G. Gill, E. Bayliss, C. Saunders, S. Della-Fiorentina, N. Kling, I. Campbell, G. B. Mann, A. S. Coates, V. GebSKI, L. Davies, R. Thornton, L. Reaby, J. Cuzick & M. Green on behalf of the Australia and New Zealand Breast Cancer Trials Group 806

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

H. Bonnefoi, T. Grellety, O. Tredan, M. Saghatchian, F. Dalenc, A. Mailliez, T. L'Haridon, P. Cottu, S. Abadie-Lacourtoisie, B. You, M. Mousseau, J. Dauba, F. Del Piano, I. Desmoulins, F. Coussy, N. Madranges, J. Grenier, F. C. Bidard, C. Proudhon, G. MacGrogan, C. Orsini, M. Pulido & A. Gonçaves 812

The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis

C. G. Rusthoven, R. A. Rabinovitch, B. L. Jones, M. Koshy, A. Amini, N. Yeh, M. W. Jackson & C. M. Fisher 818

Identifying the potential long-term survivors among breast cancer patients with distant metastasis

E. S. Lee, S. Y. Jung, J. Y. Kim, J. J. Kim, T. K. Yoo, Y. G. Kim, K. S. Lee, E. S. Lee, E. K. Kim, J. W. Min, W. Han, D. Y. Noh & H. G. Moon 828

Continued overleaf

gastrointestinal tumors

Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study

K. Bujko, L. Wyrwicz, A. Rutkowski, M. Malinowska, L. Pietrzak, J. Kryński, W. Michalski, J. Olędzki, J. Kuśnierz, L. Zając, M. Bednarczyk, M. Szczepkowski, W. Tarnowski, E. Kosakowska, J. Zwoliński, M. Winiarek, K. Wiśniowska, M. Partycki, K. Bęczkowska, W. Polkowski, R. Styliński, R. Wierzbiński, P. Bury, M. Jankiewicz, K. Paprota, M. Lewicka, B. Ciseł, M. Skórzewska, J. Mielko, M. Bębenek, A. Maciejczyk, B. Kapturkiewicz, A. Dybko, Ł. Hajac, A. Wojnar, T. Leśniak, J. Zygulska, D. Jantner, E. Chudyba, W. Zegarski, M. Las-Jankowska, M. Jankowski, L. Kołodziejewski, A. Radkowski, U. Żelazowska-Omiotek, B. Czeremczyńska, L. Kępka, J. Kolb-Sielecki, Z. Toczko, Z. Fedorowicz, A. Dżiki, A. Danek, G. Nawrocki, R. Sopyło, W. Markiewicz, P. Kędzierawski & J. Wydmański for the Polish Colorectal Study Group **834**

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials
C. Cremolini, F. Loupakis, G. Masi, S. Lonardi, C. Granetto, M. L. Mancini, S. Chiara, R. Moretto, D. Rossini, S. Vitello, G. Allegrini, G. Tonini, F. Bergamo, G. Tomasello, M. Ronzoni, A. Buonadonna, S. Bustreo, C. Barbara, L. Boni & A. Falcone **843**

Role of major resection in pulmonary metastasectomy for colorectal cancer in the Spanish prospective multicenter study (GECMP-CCR)
J. Hernández, L. Molins, J. J. Fibla, F. Heras, R. Embún & J. J. Rivas on behalf of the Grupo Español de Metástasis Pulmonares de Carcinoma Colo-Rectal (GECMP-CCR) de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) **850**

Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)
D. Koerberle, J.-F. Dufour, G. Demeter, Q. Li, K. Ribi, P. Samaras, P. Saletti, A. D. Roth, D. Horber, M. Buehlmann, A. D. Wagner, M. Montemurro, G. Lakatos, J. Feilchenfeldt, M. Peck-Radosavljevic, D. Rauch, B. Tschanz & G. Bodoky for the Swiss Group for Clinical Cancer Research (SAKK) **856**

thoracic tumors

Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer

M. Jamal-Hanjani, G. A. Wilson, S. Horswell, R. Mitter, O. Sakarya, T. Constantin, R. Salari, E. Kirkizlar, S. Sigurjonsson, R. Pelham, S. Kareht, B. Zimmermann & C. Swanton **862**

urogenital tumors

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
S. Nilsson, P. Cislo, O. Sartor, N. J. Vogelzang, R. E. Coleman, J. M. O'Sullivan, J. Reuning-Scherer, M. Shan, L. Zhan & C. Parker **868**

Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014
N. Adra, S. K. Althouse, H. Liu, M. J. Brames, N. H. Hanna, L. H. Einhorn & C. Albany **875**

A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)
T. Powles, J. Brown, J. Larkin, R. Jones, C. Ralph, R. Hawkins, S. Chowdhury, E. Boleti, A. Bhal, K. Fife, A. Webb, S. Crabb, T. Geldart, R. Hill, J. Dunlop, P. E. Hall, D. McLaren, C. Ackerman, L. Beltran & P. Nathan **880**

hematologic malignancies

Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan
A. Yoshimi, T. Toya, Y. Nannya, K. Takaoka, K. Kirito, E. Ito, H. Nakajima, Y. Hayashi, T. Takahashi, A. Moriya-Saito, K. Suzuki, H. Harada, N. Komatsu, K. Usuki, M. Ichikawa & M. Kurokawa **887**

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era
C. Y. Cheah, D. Chihara, M. Ahmed, R. E. Davis, L. J. Nastoupil, K. Phansalkar, F. B. Hagemeister, L. E. Fayad, J. R. Westin, Y. Oki, M. A. Fanale, J. E. Romaguera, M. L. Wang, H. Lee, F. Turturro, F. Samaniego, M. A. Rodriguez, S. S. Neelapu & N. H. Fowler **895**

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma
G. Fouquet, B. Pegourie, M. Macro, M. O. Petillon, L. Karlin, D. Caillot, M. Rousset, B. Arnulf, C. Mathiot, G. Marit, B. Kolb, A. M. Stoppa, S. Brechiniac, V. Richez, P. Rodon, A. Banos, M. Wetterwald, L. Garderet, B. Royer, C. Hulin, L. Benbouker, O. Decaux, M. Escoffre-Barbe, J. P. Fermand, M. Attal, H. Avet-Loiseau, P. Moreau, T. Facon & X. Leleu on behalf of IFM (Intergroupe Francophone du Myélome) **902**

Continued overleaf

head and neck tumors

- Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer
V. M. Villaflor, J. M. Melotek, T. G. Karrison, R. J. Brisson, E. A. Blair, L. Portugal, J. A. De Souza, D. T. Ginat, K. M. Stenson, A. Langerman, M. Kocherginsky, M. T. Spiotto, N. Hannigan, T. Y. Seiwert, E. E. W. Cohen, E. E. Vokes & D. J. Haraf **908**

miscellaneous tumors

- Merkel cell carcinoma: value of sentinel lymph-node status and adjuvant radiation therapy
A. Servy, E. Maubec, P. E. Sugier, F. Grange, S. Mansard, T. Lesimple, E. Marinho, B. Couturaud, A. Girod, S. Albert, R. Dendale, E. Calitchi, L. Sarda, J. Chanal, L. Deschamps, X. Sastre-Garau, L. Laroche, B. Crickx & M. F. Avril **914**

early drug development

- What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
A. Drilon, G. Li, S. Dogan, M. Gounder, R. Shen, M. Arcila, L. Wang, D. M. Hyman, J. Hechtman, G. Wei, N. R. Cam, J. Christiansen, D. Luo, E. C. Maneval, T. Bauer, M. Patel, S. V. Liu, S. H. I. Ou, A. Farago, A. Shaw, R. F. Shoemaker, J. Lim, Z. Hornby, P. Multani, M. Ladanyi, M. Berger, N. Katabi, R. Ghossein & A. L. Ho **920**

epidemiology

- The global decrease in cancer mortality: trends and disparities
D. Hashim, P. Boffetta, C. La Vecchia, M. Rota, P. Bertuccio, M. Malvezzi & E. Negri **926**
- Cancer mortality in cohorts of workers in the European rubber manufacturing industry first employed since 1975
M. Boniol, A. Koechlin, B. Świątkowska, T. Sorahan, J. Wellmann, D. Taeger, K. Jakobsson, E. Pira, P. Boffetta, C. La Vecchia, C. Pizot & P. Boyle **933**
- Periodontal disease and risk of all cancers among male never smokers: an updated analysis of the Health Professionals Follow-up Study
D. S. Michaud, K. T. Kelsey, E. Papathanasiou, C. A. Genco & E. Giovannucci **941**

sarcoma

- A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma
S. Thomas, R. Aggarwal, T. Jahan, C. Ryan, T. Troung, A. M. Cripps, P. Raha, K. T. Thurn, S. Chen, J. A. Grabowsky, J. Park, J. Hwang, A. Daud & P. N. Munster **947**

letters to the editor

- Ovarian suppression during chemotherapy increases pregnancy rate in survivors
Z. Blumenfeld **953**
- Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib
N. Takegawa, H. Hayashi, N. Iizuka, T. Takahama, H. Ueda, K. Tanaka, M. Takeda & K. Nakagawa **953**
- Prognostic impact of extracapsular lymph node involvement in colorectal cancer
Q. Huang & X. Qin **955**
- Extranodal extension is an important prognostic parameter for both colonic and rectal cancer
C. Luchini, A. Nottegar, A. Pea, M. Solmi, B. Stubbs, P. Capelli, G. Sergi, E. Manzato, M. Fassan, L. D. Wood, A. Scarpa & N. Veronese **955**
- Prognostic impact of extra-nodal extension on colon and rectal cancer should be investigated separately
Q. Huang & H. Yang **956**
- Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma' by Rosati et al.
R. B. Hines & R. Al-Rajabi **957**
- Reply to the letter to the editor 'Number-Needed-To-Treat for pricing costly anti-cancer drugs. The example of Regorafenib in metastatic colorectal cancer' by Graziano et al.
F. Pignatti, J. Martinalbo, B. Jonsson & P. Foggi **958**
- Dendritic cells stimulated by MUC1 antigen could induce lymphocytes' anergy through PD-L2 but not through PD-L1 pathway
K. Wojas-Krawczyk, I. Homa-Mlak, P. Krawczyk, T. Kucharczyk & J. Milanowski **958**